Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.94 USD
Change Today -0.07 / -0.19%
Volume 469.8K
SNN On Other Exchanges
Symbol
Exchange
London
New York
OTC US
Frankfurt
Frankfurt
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc -spon adr (SNN) Snapshot

Open
$36.91
Previous Close
$37.01
Day High
$37.04
Day Low
$36.64
52 Week High
12/23/14 - $39.80
52 Week Low
10/16/14 - $28.87
Market Cap
16.5B
Average Volume 10 Days
429.1K
EPS TTM
--
Shares Outstanding
447.3M
EX-Date
04/15/15
P/E TM
--
Dividend
$0.74
Dividend Yield
1.60%
Current Stock Chart for SMITH & NEPHEW PLC -SPON ADR (SNN)

Related News

No related news articles were found.

smith & nephew plc -spon adr (SNN) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc -spon adr (SNN) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopedic reconstruction products, including hip and knee implants, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints. In addition, this segment offers arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue; and gynecological instrumentation devices. The company’s Advanced Wound Management segment offers a range of products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds. This segment also provides traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

14,000 Employees
Last Reported Date: 07/30/15
Founded in 1856

smith & nephew plc -spon adr (SNN) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $3.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $1.8M
Compensation as of Fiscal Year 2014.

smith & nephew plc -spon adr (SNN) Key Developments

Smith & Nephew plc Declares Interim Dividend for the First Half of 2015, Payable on October 27, 2015

Smith & Nephew plc announced that its Board confirmed that the interim dividend for the first half of 2015 is 11.8 per share (23.6 per ADS), compared with 11.0 last year. This will be paid on October 27, 2015 to shareholders on the register at the close of business on October 09, 2015.

Smith & Nephew plc Appoints Robin Freestone as Non-Executive Director and Member of the Audit Committee, Effective September 1, 2015

Smith & Nephew announced that Robin Freestone is to join its Board as non-executive director and member of the audit committee on 1 September 2015. Robin has been Chief Financial Officer of Pearson plc since 2006, and is retiring from this executive role on 1 August 2015. Previously he was Deputy Chief Financial Officer at Pearson and prior to that, he held a number of senior financial positions at Amersham plc from 2000 to 2004.

Smith & Nephew plc Reports Consolidated Unaudited Revenue Results for the Second Quarter and Earnings Results for the Six Months Ended June 27, 2015; Provides Earnings Guidance for the Year 2015

Smith & Nephew Plc reported consolidated unaudited revenue results for the second quarter and earnings results for the six months ended June 27, 2015. For the quarter, the company reported revenue of $1,168 million against $1,147 million a year ago. For the six months, the company reported revenue of $2,272 million against $2,220 million a year ago. Operating profit was $439 million against $363 million a year ago. Profit before taxation was $411 million against $349 million a year ago. Attributable profit was $295 million or 32.8 cents per diluted share against $239 million or 26.6 cents per diluted share a year ago. Net cash inflow from operating activities was $490 million against $233 million a year ago. Capital expenditure was $161 million against $161 million a year ago. Net debt as at 27 June 2015 was $1,513 million. Trading profit grew ahead of this at 6% underlying, resulting in a trading margin of 22.5%, a 70 basis point improvement over last year. EPSA was $0.391, a reported growth of 3%, negatively impacted by currency, which I'll return to later. Trading cash flow was $382 million and the conversion rate of 75% compared with the 53% in the prior period. Finally, free cash generation was $329 million, including the receipt of a legal settlement of $99 million. The company continues to expect to deliver higher underlying revenue growth in 2015 than in 2014 and a year-on-year improvement in trading profit margin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNN:US $36.94 USD -0.07

SNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $196.19 USD -0.46
Edwards Lifesciences Corp $151.09 USD -1.07
Olympus Corp ¥4,760 JPY +20.00
St Jude Medical Inc $73.40 USD -0.42
Zimmer Biomet Holdings Inc $104.33 USD +0.26
View Industry Companies
 

Industry Analysis

SNN

Industry Average

Valuation SNN Industry Range
Price/Earnings 30.0x
Price/Sales 3.6x
Price/Book 4.1x
Price/Cash Flow 29.8x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC -SPON ADR, please visit www.smith-nephew.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.